Our liquid biopsy comprehensive genomic profiling service for patients with solid tumours.1,2
Foundation Medicine is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
FoundationOne® Liquid is an additional CGP service for patients with solid tumours.1,2 FoundationOne® Liquid provides an alternative biopsy service for patients that are not suitable candidates for CGP with FoundationOne® CDx.2 Liquid biopsy may provide an opportunity to perform non-invasive, blood-based genomic profiling when:3
FoundationOne® Liquid extends the benefits of CGP to additional clinical situations with a single blood draw. 5‡ Liquid biopsies are a non-invasive tool for biomarker testing, which may replace the use of invasive solid tumour biopsies (associated with complications and increased morbidity). As liquid biopsies can be scheduled more frequently during treatment, measurements of tumour burden and early evidence of recurrence or resistance can be identified across several time points. Liquid biopsy may also better reflect the genetic profile of an individual tumour as it provides a full snapshot of information, unlike tissue biopsies which only reflect the specific area of the tumour biopsied.9
Clinicians should primarily use FoundationOne® CDx where tissue is available; when tissue biopsy is not feasible, there is insufficient tissue for analysis and/or when disease progression is suspected, FoundationOne® Liquid may offer a suitable alternative.2–4
For more information about the ordering process, contact the Roche Foundation Medicine Customer Care Team:
Freephone: 0800 731 5711
For technical and scientific enquiries related to the Foundation Medicine service, please contact the Medical Information team on:
Freephone: 0800 328 1629
Experience how FoundationOne® Liquid could guide treatment decision-making with samples from a single blood draw.
*Base substitutions, insertions or deletions, copy number alterations and gene rearrangements.
†FoundationACT is a prior version of FoundationOne® Liquid which analysed 62 genes and has been analytically validated.2
‡Two tubes of whole peripheral blood are required (8.5 ml per tube) per patient.5
CGP: comprehensive genomic profiling; ctDNA: circulating tumour DNA; MSI: microsatellite instability.
RXUKRFMI00099 November 2019